Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MesoPher with extended pleurectomy/decortication after chemotherapy in resectable mesothelioma
NL-OMON52279Phase 1Recruiting
- Sponsor
- Erasmus MC
- Start
- Dec 2021
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MesoPher in pleural mesothelioma, sponsored by Erasmus MC. Primary endpoint: Feasibility. Started Dec 2021; status: recruiting.
02
Drugs
MesoPher
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NL-OMON52279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52279.